ANNUAL RESULTS
UNLIMITED
POTENTIAL
Currently viewing: 1.3 OPERATING (LOSS)/ PROFIT | Next: 1.4 Finance costs and finance income
|
Notes |
2026 R’000 |
2025 R’000 |
||
|---|---|---|---|---|
|
The following has been charged/(credited) in arriving at operating (loss)/ profit: |
||||
|
Advertising and promotional expenses1 |
211 961 |
54 275 |
||
|
Audit fees – services as auditors relating to the year-end audit2 |
26 989 |
19 379 |
||
|
Audit fees – other3 |
1 677 |
- |
||
|
Consulting fees4 |
146 702 |
50 201 |
||
|
Foreign exchange (gain)/loss |
(892) |
1 578 |
||
|
Gain on effective settlement of pre-existing relationships upon obtaining control1 of Cell C |
(480 707) |
– |
||
|
Gain on settlement by Cell C of leases with Dark Fibre Africa5 |
(355 832) |
– |
||
|
Impairment of inventory |
17 424 |
8 034 |
||
|
Insurance6 |
34 137 |
27 600 |
||
|
IT infrastructure costs and computer-related costs7 |
85 136 |
76 831 |
||
|
Legal fees8 |
4 417 |
11 569 |
||
|
Licence fees9 |
150 291 |
87 076 |
||
|
Loss on disposal of property, plant and equipment |
3 163 |
1 998 |
||
|
Loss on disposal of intangible assets |
37 092 |
– |
||
|
Loss on disposal of subsidiary – Cell C (including CEC) |
6 027 454 |
– |
||
|
Loss on disposal of subsidiary – other |
105 060 |
– |
||
|
Loss on in-substance written call option over Cell C shares issued to Sisonke Growth Partners Proprietary Limited |
140 000 |
– |
||
|
Loss on written put option over Cell C shares issued to Nedbank and Lesaka |
141 117 |
– |
||
|
Motor vehicle expenses10 |
11 578 |
11 450 |
||
|
Software development and IT project costs |
56 999 |
70 390 |
||
|
Staff training11 |
45 528 |
52 492 |
||
|
Transaction costs related to the restructuring, unbundling and the listing of Cell C12 |
318 992 |
– |
||
|
Travel – local and overseas13 |
24 837 |
17 544 |
||
|
Impairments of goodwill comprise the following: |
||||
|
Impairment of goodwill arising on Glocell Distribution Proprietary Limited |
161 697 |
– |
||
|
Impairment of goodwill – other |
38 895 |
– |
||
|
200 592 |
– |
|||
|
Fair value movements comprise the following: |
||||
|
Fair value gain on surety receivable |
(2 200) |
(2 883) |
||
|
Net fair value gain on financial instruments |
21 896 |
(171 433) |
||
|
Fair value gain on Preference shares B |
(242 637) |
– |
||
|
(222 941) |
(174 316) |
|||
|
Bad debts and expected credit loss comprise the following: |
||||
|
Bad debts and expected credit loss on loans |
(9 469) |
(284 981) |
||
|
Bad debts and expected credit losses on trade receivables, other receivables and advances to customers |
224 994 |
520 505 |
||
|
215 525 |
235 524 |
|||
|
Modification/derecognition of financial instruments comprise the following: |
||||
|
TPC |
||||
|
(Gain)/loss on modification of financial liability – Class A Preference Shares |
(43 238) |
18 769 |
||
|
Gain on derecognition of financial liability – SPV5 |
(165 216) |
– |
||
|
Loss on modification of financial liability – Gramercy |
15 792 |
– |
||
|
CEC |
||||
|
Loss on derecognition of financial assets measured at amortised cost |
– |
34 103 |
||
|
(192 662) |
52 872 |
| 1 | Included in 2026 is R150.6 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 2 | Included in 2026 is R4.8 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 3 | Included in 2026 is R1.7 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 4 | Included in 2026 is R76.6 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 5 | Included in 2026 is R355.8 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 6 | Included in 2026 is R8.9 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 7 | Included in 2026 is R6.2 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 8 | Included in 2026 is R0.9 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 9 | Included in 2026 is R59.6 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 10 | Included in 2026 is R1.9 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 11 | Included in 2026 is R2.0 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 12 | Included in 2026 is R232.5 million incurred by Cell C for the three-month period consolidated September to November 2025. |
| 13 | Included in 2026 is R2.1 million incurred by Cell C for the three-month period consolidated September to November 2025. |